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ABSTRACT 
A 28-day repeated dose study in rats (OECD407) enhanced for endocrine and immune 
parameters was performed with hexabromocyclododecane (HBCD). Rats were exposed by 
daily gavage to HBCD dissolved in corn oil in 8 dose groups with doses ranging between 0 
and 200 mg/kg bw per day (mkd). Evaluation consisted of dose-response analysis with 
calculation of a benchmark dose at the lower 95% one-sided confidence bound (BMDL) at 
predefined critical effect sizes (CESs) of 10–20%. The most remarkable findings were dose-
related effects on the thyroid hormone axis, that is, decreased total thyroxin (TT4, BMDL 55.5 
mkd at CES – 10%), increased pituitary weight (29 mkd at 10%) and increased 
immunostaining of TSH in the pituitary, increased thyroid weight (1.6 mkd at 10%), and thyroid 
follicle cell activation. These effects were restricted to females. Female rats also showed 
increased absolute liver weights (22.9 mkd at 20%) and induction of T4-glucuronyl transferase 
(4.1 mkd at 10%), suggesting that aberrant metabolization of T4 triggers feedback activation 
of the thyroid hormone system. These effects were accompanied by possibly secondary 
effects, including increased cholesterol (7.4 mkd at 10%), increased tibial bone mineral 
density (> 49 mkd at 10%), both in females, and decreased splenocyte counts (0.3–6.3 mkd 
at 20%; only evaluated in males). Overall, female rats appeared to be more sensitive to HBCD 
than male rats, and an overall BMDL is proposed at 1.6 mkd, based on a 10% increase of the 
thyroid weight, which was the most sensitive parameter in the sequence of events.  
INTRODUCTION 
  
Hexabromocyclododecane (HBCD) is a brominated flame retardant (BFR) which has its main 
application in textile industry and in polystyrene foam for building construction (Hutzinger and 
Thoma, 1987). The compound is simply blended with polymers and, therefore, more likely to 
leach out of products than covalently bound flame retardants. Indeed, HBCD has been 
identified as a contaminant of environmental significance (Letcher and Behnisch, 2003). In 
aquatic biota in polluted areas, levels of HBCD are comparable to other BFRs, such as 
tetrabromobisphenol-A and some polybrominated biphenylethers (Morris et al., 2004; 
Sellstrom et al., 2003), although the production volume of HBCD is lower than of those other 
BFRs. Low but significant exposure levels of this potentially persisting and bioaccumulating 
compound are found in humans with a fluctuating increase over time (Fängström et al., 2006; 
Ryan et al., 2006). Intake via food is possibly the largest source of human HBCD exposure, 
although inhalation and dermal routes may contribute significantly, notably, in occupational 
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exposure (KEMI, 2003). Therefore, the use of this compound is a reason for environmental 
and health concern (Alaee et al., 2003).  
The current toxicological database on HBCD is too limited to form a solid basis for an 
integrated risk assessment, combining data from effect and exposure studies in multiple 
species and environmental levels (Letcher and Behnisch, 2003). HBCD has been tested in a 
28-day toxicity study in rats showing a lowest observed effect level of 125 mg/kg on the basis 
of liver weight effects, but no hormonal parameters were addressed (Chengelis, 1997; cited in 
KEMI, 2003). In a 90-day toxicity study, also in rats, liver weight increases were found at 100 
mg/kg and higher without observed pathology. In addition, there were effects on the thyroid 
hormone axis, that is, decreased T4 and increased TSH (Chengelis, 2001; cited in KEMI, 
2003). Furthermore, in mice, HBCD induced developmental neurotoxic effects (Eriksson et al., 
2006). Additional studies are needed to understand effects and risks of exposure to this 
compound in wildlife, humans, and their ecosystems, that is, to understand mechanisms of 
toxicity and/or biological effects and to identify risk of exposure (Darnerud, 2003).  
Therefore, the current subacute oral dose study was undertaken in rats, with a focus on 
endpoints commonly affected by persistent organic pollutants, that is, in the immune and 
endocrine domains, including effects on the thyroid hormone (TH) axis, on hematology, on 
bone size and mineralization, and on retinoid parameters (Andrews et al., 2001). So far, in line 
with the observations mentioned above, the TH system has been identified as a target for 
potential endocrine disruptive hazard of BFRs in general (Legler and Brouwer, 2003). 
Interaction of BFRs with the TH system was mainly described at the level of TH metabolism; 
several BFRs inhibit TH sulfation, modulate deiodination, and induce glucuronidase and 
uridine diphosphate (UDP) glucuronyl transferase. Further BFR interactions with the TH 
system are known at the level of transport, for example, competition with T4 on transthyretin 
(TTR), thus possibly facilitating transport over the placenta and the blood-brain barrier.  
The rationale to test the endocrine effects of HBCD in the in vivo model in this study was 
supported by results from in vitro tests with indicator cell lines sensitive to endocrine activity, 
which showed that HBCD can interact with multiple hormone systems, particularly with TH-
mediated cell proliferation and with progesterone receptors, and to a lesser extent with 
estrogen, androgen, and dioxin (arylhydrocarbon) receptors (Hamers et al., 2006), while 
significant enhancement of TH-receptor (TR)–mediated gene expression was confirmed in 
HeLa TR cells (Yamada-Okabe et al., 2005).  
ANIMALS, MATERIALS, AND METHODS 
  
Forty Wistar rats (RIVM Cpb:WU) of both sexes, aged 7 weeks, were purchased from the 
RIVM breeding facilities (three to four generations after original purchase from HsdCpb:WU 
Harlan, Horst, NL) and housed individually to allow recording of individual feed consumption, 
and to avoid bias from hierarchical stress. Housing was in plastic Macrolon cages of 
appropriate sizes with stainless steel wire cover and chopped wood bedding. Light/dark 
regime was 12/12 h. Standard pelleted rat feed without soy (RMH-GS, Hope Farms/ABDiets, 
Woerden, NL; this standardized formulation contains ca 18,800 IU vit.A/kg) and drinking water 
were supplied ad libitum. HBCD (technical mixture containing traces of tetra- and 
pentabromocyclododecane) was obtained as a composite mix through Bromine Science and 
Environmental Forum (BSEF, with kind cooperation of Dr Klaus Rothenbacher). The technical 
preparation is a mixture of three enantiomers, HBCD- , -ß, and - , and their respective 
proportion in the used batch was 10.28, 8.72, and 81.01%. It was dissolved in corn oil via 
primary solution in acetone, which was evaporated afterward. Target dosing was 0, 0.3, 1, 3, 
10, 30, 100, and 200 mkd; the highest dose depended on maximum HBCD solubility in corn 
oil. Appropriate concentrations of HBCD in corn oil were based on daily gavage of 5 ml/kg bw.  
The experimental protocol followed the OECD407 28-day subacute toxicity guideline, which 
was enhanced for endocrine and immunological endpoints (Andrews et al., 2001). However, 
in contrast to the published protocol, the animals were distributed among more dose groups 
each with fewer animals, that is, five rats per sex per dose group, for improved assessment of 
dose-response relationships (Kavlock et al., 1996; Slob, 2002).  
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Exposure started at the age of 11 weeks. Animals were inspected daily for general condition 
and clinical abnormalities. Beddings were changed weekly, at which time rats were submitted 
to in-hand observations and reaction to handling, and their body weight and feed consumption 
was recorded.  
At the end of the exposure period, animals were necropsied in the course of 5 days, resulting 
in a total of 28–33 days of exposure. Necropsies were performed in a targeted manner to 
avoid clustering of animals from single exposure groups on one day and to allow clustered 
immunological analysis which was only performed in males to avoid variability due to the 
estrous cycle. Targeted necropsy of females in the first day of diestrous was abandoned 
because staging of the estrous cycle on the basis of vaginal smears was not completely 
consistent with further histological staging of uterus and vagina epithelium. Euthanasia was 
achieved by exsanguination from the abdominal aorta under carbon dioxide anesthesia.  
During necropsy, blood was collected and the following organs were dissected: 
skin/mammary gland, liver, pancreas, spleen, thymus, heart, lungs, stomach, duodenum, 
ileum, jejunum, colon, ceacum, ovaries, uterus, urine bladder, kidney, adrenals, 
trachea/thyroid gland, brain, pituitary gland, testes, epididymis, seminal vesicles with 
coagulation gland, prostate, popliteal lymph nodes, ischiadic nerve, fat, muscle, bone marrow 
(from femur), sternum, and thoracic spine. All organs were visually inspected and weighed 
directly after dissection or after fixation (thyroid, pituitary) to reduce mechanical damage. 
Sperm was collected from the cauda epididymis for direct analysis of motility and morphology. 
Defined samples of the liver, intestines, brain, adrenals, testes, ovaries, muscle, and fat were 
snap frozen in liquid nitrogen and stored at – 80°C. Plasma aliquots were stored at – 20°C. A 
sample of whole blood and part of the spleen were freshly analyzed. All remaining dissected 
organs were fixed in standard formalin for further histological processing. In these collected 
tissues, the following endpoints were addressed: sperm quantity and quality (cauda 
epididymis sperm), cellular composition (blood, bone marrow), immune cell subpopulations 
and natural killer (NK) activity (spleen), thyroid hormones (plasma), clinical plasma 
components (plasma), HBCD kinetics (liver, fat), metabolic activity (liver), and histopathology 
(all prepared tissues/organs). A distal body preparation, including lumbar vertebrae, pelvic 
bones, and one intact hind limb, was frozen at – 20°C for later dissections and analysis of 
bone parameters.  
Experiments were approved by the institutional Committee on Animal Experimentation, 
according to Dutch legislation.  
Compound analysis. 
Internal dosing was verified by analysis of HBCD enantiomers in liver of three animals per 
dose group and in a limited number of fat samples. Liver was chosen because sufficient 
material is available for analysis of measurable quantities of the compound and potentially 
also of metabolites. The liver sample (about 100 mg) was weighed, dried with sodium 
sulphate (Merck, Darmstadt, Germany), and stored for 2 h. The dried sample was extracted 
using a Soxhlet apparatus with hexane:acetone (3:1, vol/vol, Promochem, Wesel, Germany), 
with a starting volume of 100 ml. After extraction, 1 ml of 13C-labeled -, ß-, -HBCD (100 
ng/ml, CIL, Andover, MA) was added, and the extracts were evaporated to 10 ml. An aliquot 
of the extract (1/10) was dried with nitrogen to determine the lipid content gravimetrically. The 
residual extract was treated with 1 ml concentrated sulfuric acid (Merck) to remove the lipids. 
This step was two times repeated, and the combined hexane extract was further purified with 
silica gel. Silica gel was eluted with 11 ml isooctane and 29 ml isooctane:diethyl ether (85:15, 
vol/vol, Promochem). Finally, the silica eluate was evaporated to almost dryness with 
nitrogen, and 1 ml of methanol was added. The -, ß-, -HBCD diastereomers were 
determined with LC-MS/MS (LCQ Advantage, Thermo Finnigan, Austin, TX) using 
electrospray ionization. Identification of HBCD was based on the retention times of the 13C-
labeled compounds and the bromine clusters of the adduct ion m/z 677 and fragment ion m/z 
644. The m/z 644 ion was used for quantification. A Zorbax Eclipse XDB-C18 HPLC column 
(2.1 x 150 mm, 3.5 µm, Agilent, Palo Alto, CA) was used with a gradient of ammonium 
chloride (0.1mM) and acetonitrile (ACN) starting from 0 to 6 min at ammonium chloride:ACN 
(3:1, vol/vol); followed by ammonium chloride:ACN (1:9, vol/vol) from 6 to 10 min.  
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Measurement of the HBCD-ß enantiomer in a selected number of tissue samples showed that 
this isomer only comprised a minor fraction of the total HBCD (< 1.5%; data not shown); 
measurements in the full experimental set were therefore restricted to the HBCD-  and -  
enantiomers.  
HBCD partitions to adipose tissue (Yu and Atallah, 1980; cited in KEMI, 2003), therefore, 
internal concentrations in the liver in this study are expressed on lipid basis.  
Organ weights. 
The relationship between organ weight and body weight in a growing animal is allometric of 
nature for most organs with allometric constants that vary by organ and also by stage of organ 
ontogeny (Trieb et al., 1976). Analysis of relative organ weights does not eliminate the indirect 
effect of treatment on organ weight via its effect on body weight and was even suggested to 
be unreliable (Shirley, 1977; Trieb et al., 1976). Furthermore, changes in body fat, muscularity, 
or bone density, all potential specific effects of endocrine disruption, may confound the 
conclusions of relative organ weights. To avoid this as well as complex and/or uncommon 
approaches such as to adjust each organ weight by its specific allometric exponent of the 
body weight, or to differentiate between organs for the specific use of body or brain as a 
reference, or to use body weight as a covariate (Bailey et al., 2004; Trieb et al., 1976), 
analysis of organ weights was restricted to independent dose-response analysis of absolute 
organ weights. The observed organ weight changes were then interpreted in the context of 
concomitant other changes, particularly of body weight but also of other organs.  
Histology. 
After fixation (and subsequent weighing, see above), organs sampled for histology were 
dehydrated and paraffinized and embedded according to standard sampling and trimming 
procedures. Sections of 4 µm were stained with hematoxylin and eosin in an automated way. 
Microscopic observations were done by comparison of control and exposed samples. Scoring 
thyroid gland histopathology was done by semiquantitative assessment of parameters of 
thyroid activation (follicular cell size, nuclear size, vacuolization), and of follicle size, without 
knowledge of treatment. For each parameter, four relative stages were discerned (control, 
slight, moderate, and severe). Effects on TSH in thyrotropic cells in the adenohypophysis were 
assessed by immunohistochemistry. For this purpose, paraffin sections of routinely 
processed, formalin fixed, pituitaries were deparaffinized in a graded series of xylol/ethanol. 
Endogenous peroxidase activity was blocked in a 1/1 methanol/distilled water solution with 
1/100 0.3% H2O2 added. Antigen exposure was improved by 30 min trypsin incubation (0.25% 
wt/vol trypsin with 0.02% wt/vol CaCl2 in distilled water), and background staining was 
reduced by 15 min incubation with blocking reagent (PerkinElmer, Wellesley, MA) and 1% 
wt/vol in phosphate-buffered solution. Subsequent 60 min incubation with purified rabbit 
polyclonal IgG against rat TSH (Biogenesis, Ede, The Netherlands), 1/1000 dilution was 
followed by incubation with a biotinylated anti-rabbit second antibody (1/200, 30 min; Vector, 
Burlingame, CA) and avidin-biotin complex (Vector) according to instructions of the 
manufacturer; both antisera were diluted in the 1% blocking reagent solution. Immunostaining 
was completed with incubation with a standard diaminobenzidine (Sigma, St Louis, MO) 
solution for 5 min. Counterstaining was with hematoxylin (Mayer procedure). Immunostaining 
intensity was evaluated by measuring pixel saturation on standardized digital images of 
comparable areas in each pituitary, using image analysis software (AnalySIS, Olympus Soft 
Imaging Solutions, Münster, Germany). Saturation profiles were classified compared with two 
sample cells, representing low- and high-intensity staining, and ratios of low/high-intensity 
pixels were calculated for each image/pituitary.  
Immunology/hematology. 
For hematology, one femoral shaft was flushed with 4 ml ICP (Impulse Cytophotometer) 
solution, containing 3.22 g/l trisodium-citrate-dihydrate, 3.4 g/l sodium-dihydrogenphosphate-
dihydrate, 3.87 g/l disodium-hydrogenphosphate-dihydrate, 1.17 g/l citric-acid-monohydrate, 
3.65 g/l dextrose, 4.96 g/l sodiumchloride in demineralized water, pH 7.4 at 20°C. The 
resulting cell suspension and the collected EDTA blood were kept at 4°C until automated 
analysis in an ADVIA120 (Bayer, Leverkusen, Germany) within 4 h. Analysis of the spleen 
subpopulations (T-lymphocytes (CD3), T-helper (CD4), cytotoxic T cells (CD8), NK cells 
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(CD161a), and B-lymphocytes (CD45RA), was done on fixed cell suspensions prepared of 
approximately one third of the organ, with a FACS-Calibur (B&D, Franklin Lakes, NJ) in two 
separate runs. Numbers of these subpopulations were calculated from the ratios determined 
by fluorescence-activated cell sorter (FACS) analysis, cell counting with the Coulter Counter 
Z2 (Beckman, Fullerton, CA), and weights of spleen parts. NK-function test was essentially 
performed as described previously (de Jong et al., 1980 ), with 51Cr-labeled YAC-1 cells as 
targets, following an overnight incubation at 37°C to remove adherent cells.  
Clinical chemistry. 
Albumin, alkaline phosphatase, alanine aminotransferase, total cholesterol, creatinine, 
glucose, total protein, and urea were measured routinely as single measurement on an 
autoanalyzer (Hitachi 912, Roche Diagnostics, Basel, Switzerland) using standard kits from 
Roche Diagnostics. The measurement included hemolytic, icteric, and lipemic indices to 
exclude interferences.  
TH analysis. 
Total concentrations of circulating thyroid hormones thyroxin T4 and T3 were determined in 
serum by in-house radioimmunoassays (RIAs) (Internal Medicine Laboratory, Erasmus 
Medical Center, Rotterdam) validated for rats and mice, as described previously (Friedrichsen 
et al., 2003 ). These measurements were done in duplicate RIAs. Within-assay coefficients of 
variation amounted to 2–8% for T4 and 2–6% for T3, and between-assay coefficients of 
variation were 5–10% for T4 and 8% for T3. Based on structure differences, no interference of 
HBCD was expected in this assay.  
UDP-glucuronosyltransferase assay. 
Hepatic microsomal fractions were prepared by homogenizing liver samples on ice in 3 
volumes ice-cold 10mM Tris-HCl buffer (Sigma Chemicals Co), pH 7.4, containing 0.25M 
sucrose and 1mM dithiothreitol (DTT, Duchefa Biochemie, Haarlem, NL), using a Potter tube. 
The homogenate was centrifuged for 30 min at 12,000 x g and 0–4°C. The resulting 
supernatant was centrifuged for 90 min at 105,000 x g and 0–4°C, and the microsomal pellet 
was resuspended in 2 volumes ice-cold 10mM buffer containing 3mM EDTA and 1mM DTT, 
pH 7.4. Microsomal protein levels were determined using BioRad Protein reagent and BSA as 
a standard. Hepatic T4-UDP glucuronosyltransferase (UGT) activities were determined as 
described previously (Schuur et al., 1997). Briefly, microsomes (1 mg protein/ml) were 
incubated for 30 min at 37°C with 1µM T4 plus 100,000 cpm 125I-labeled T4 (Amersham, 
Buckinghamshire, UK), 3.75mM MgCl2, and 0.125% BSA (Sigma) in the presence or absence 
(blank) of 5mM UDP-glucuronyl acid (Sigma) as a cofactor in 200 µl 75mM Tris-HCl, pH 7.8. 
Reactions were stopped by the addition of 0.2 ml ice-cold methanol. After centrifugation, 0.2 
ml supernatant was mixed with 0.8 ml 0.1M HCl and transferred to Sephadex LH-20 
minicolumns (Pharmacia, Woerden, NL). Columns were eluted with HCl to collect free 125I 
and, subsequently, with water to collect the glucuronated fraction. Hepatic microsomes from 
beta-naphthoflavone (bNF)– and corn oil–exposed rats (Meerts et al., 2000) were used as 
positive and negative controls, respectively, throughout all UGT assays as internal reference. 
Maximal T4-UGT activities induced by HBCD in this experiment were approximately 50% of 
those induced by the internal reference bNF (2.0 ± 0.4 pmol/min/mg protein).  
Apolar retinoid analyses. 
Apolar retinoids were extracted from liver homogenates (20% wt/vol in water) using 
diisopropyl ether and separated on a Nucleosil C18 5-µm HPLC column using an ethanol:water 
gradient elution as described previously (Nilsson et al., 1996). Retinol and retinyl esters were 
detected with a JASCO 821-FP fluorescence detector and quantified using internal and 
external standards.  
Bone analyses. 
Dissected left femur and tibia were cleaned from soft tissue and stored in Ringer solution (1 l 
contains 0.3 g Tris, 0.24 g CaCl2(H20)2, 0.4 g KCl, and 2.05 ml 1M HCl, pH 7.4) stored in – 
20°C until analysis. The length of each bone was measured using an electronic sliding caliper 
to the nearest 0.01 mm (IP65, Sylvac SA, Crissier, Switzerland). The bones were scanned 
using the peripheral quantitative computed tomography (pQCT) system (Stratec XCT 
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Research SA+) with software version 5.50 (Norland Stratec Medizintechnik, GmbH, 
Birkenfeld, Germany) as described elsewhere (Stern et al., 2005). Diaphyseal pQCT scans of 
femur and tibia were performed at sites distanced 50% of total bone length from the end of the 
bone to determine cortical bone parameters. Metaphyseal pQCT scans, at sites distanced 
15% (male and female) of total bone length from the distal end of femur and at 12% (male) or 
15% (female) from the proximal end of tibia, were performed to measure total and trabecular 
bone parameters.  
Statistical analysis. 
Dose-response analysis of effects, based on external dosing (mg/kg bw) was done using a 
nested family of purely descriptive (exponential) models with the PROAST software (Slob, 
2002). This method enables integrated evaluation of the complete data set. From the best 
curve fit, indicated by significance at the 5% level, a critical effect dose (CED, also referred to 
as benchmark dose, Filipsson et al., 2003) was calculated at a predefined critical effect size 
(CES) of 10 or 20% (see Tables 1 and 2 for an overview). CES is defined as the threshold 
adverse effect level, determined by expert judgment for each parameter based on knowledge 
of the pathophysiology of each effect, including irreversibility or adverse follow-up effects. In 
practice, a CES of 10% was defined as the default, considering that this effect size will cover 
the hazard for the most sensitive subjects in a population. For liver weight and immune 
parameters, a CES of 20% was defined, considering that lower effect sizes could represent a 
nontoxic physiologic response. The analysis was completed with the calculation of a 95% 
confidence interval (two-sided), thus enabling the calculation of a 5% lower confidence bound 
of the CED estimate. This value may be considered as a benchmark dose at the lower 
confidence bound (BMDL) for continuous data. The CED/BMDL ratio was used as a measure 
for the (statistical) uncertainty in a data set and, hence, for validity of the result of the dose-
response modeling. As a consequence, in case of a more than 10-fold difference between 
CED and BMDL, the data were considered uninformative. The controls were used as input for 
the modeling, although for graphical representation on a log scale, an approximation is used.  
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TABLE 1 Significant HBCD-Induced Dose-Response Effects in Female Rats  
 Organ weights 
 
Plasma chemistry 
 
Liver chemistry 
 
 Total bonea 
 
Trabecular 
bonea 
 
                   Femur 
 
Femur 
 
Tibia 
 
HBCD dose 
mg/kg bw 
n Pituitary 
(mg) 
Thyroid 
(mg) 
Liver 
(g) 
n ALP 
(U/l) 
CHOL 
(mmol/l) 
GLU 
(mmol/l) 
Total 
protein 
(g/l) 
Albumin 
(g/l) 
n TT4 
(nmol/l) 
TT3 
(nmol/) 
T4-UGT 
(pmol/min/mg 
protein)b 
Retinyl 
palmitate 
(nmol/g 
liver) 
Retinol 
(nmol/g 
liver) 
Sum 
retinoids 
(nmol/g 
liver) 
n Area 
(mm2) 
Mineral 
content 
(mg/mm) 
Mineral 
density 
(mg/cm3) 
 
0 5 5 ± 1 17 ± 2 9.7 ± 
1.0 
5 4.7 ± 
2.9 
1.8 ± 0.2 9.8 ± 0.9 56.1 ± 
2.0 
42.0 ± 
1.6 
5 41.3 ± 
2.6 
0.91 ± 
0.10 
0.56 ± 0.23 1720 ± 297 19.1 ± 
2.9 
1987 ± 
338 
3 16.1 ± 
1.5 
10.5 ± 0.5 228 ± 
34 
199 ± 
45 
0.3 4 12 ± 1 18 ± 2 8.9 ± 
1.1 
3 3.1 ± 
2.8 
1.7 ± 0.1 9.6 ± 1.2 56.9 ± 
2.2 
43.2 ± 
1.3 
4–
5 
41.9 ± 
3.1 
0.84 ± 
0.15 
0.61 ± 0.15 1831 ± 224 28.7 ± 
12.5 
2138 ± 
234 
3 14.9 ± 
0.9 
10.2 ± 1.1 262 ± 
34 
226 ± 
53 
1 5 11 ± 3 22 ± 4 8.6 ± 
1.3 
3 4.7 ± 
2.5 
1.7 ± 03 9.8 ± 1.0 56.4 ± 
1.8 
42.6 ± 
1.4 
5 40.2 ± 
7.3 
0.88 ± 
0.12 
0.53 ± 0.17 1690 ± 301 26.2 ± 
7.1 
1964 ± 
349 
4 13.7 ± 
0.6 
9.5 ± 0.6 231 ± 
40 
199 ± 
24 
3 5 13 ± 2 15 ± 4 9.5 ± 
0.4 
3 3.7 ± 
2.1 
1.9 ± 0.3 10.3 ± 
1.2 
56.3 ± 
0.7 
42.3 ± 
1.1 
5 37.2 ± 
4.7 
0.81 ± 
0.11 
0.43 ± 0.09 1542 ± 236 24.9 ± 
2.7 
1797 ± 
280 
5 14.4 ± 
0.7 
9.2 ± 0.7 219 ± 
20 
186 ± 
23 
10 5 11 ± 3 18 ± 3 8.9 ± 
0.6 
3 2.3 ± 
1.2 
1.6 ± 0.2 9.4 ± 0.4 56.8 ± 
2.4 
42.1 ± 
1.7 
5 38.6 ± 
1.7 
0.80 ± 
0.09 
0.57 ± 0.14 1368 ± 98 22.8 ± 
1.2 
1601 ± 
103 
3 14.5 ± 
0.9 
9.5 ± 1.1 211 ± 
45 
201 ± 
70 
30 5 8 ± 2 35 ± 17 11.0 
± 1.0 
4 2.4 ± 
0.3 
1.9 ± 0.3 9.8 ± 1.1 59.2 ± 
3.1 
42.6 ± 
2.8 
4–
5 
38.0 ± 
6.1 
0.74 ± 
0.15 
0.74 ± 0.22 1157 ± 122 17.1 ± 
3.5 
1354 ± 
135 
3 15.5 ± 
0.4 
9.9 ± 0.4 248 ± 
10 
181 ± 
33 
100 5 13 ± 1 27 ± 7 13.0 
± 0.5 
4 2.7 ± 
1.6 
2.4 ± 0.2 8.7 ± 0.9 64.1 ± 
1.3 
45.6 ± 
1.1 
4–
5 
35.8 ± 
5.2 
0.92 ± 
0.20 
1.39 ± 0.27 1152 ± 162 17.0 ± 
5.0 
1361 ± 
169 
3 16.2 ± 
1 
10.4 ± 0.8 228 ± 
22 
195 ± 
29 
200 5 13 ± 2 26 ± 3 11.6 
± 0.6 
3 2.4 ± 
2.7 
1.8 ± 0.2 8.1 ± 1.8 61.0 ± 
3.6 
44.2 ± 
2.6 
5 30.4 ± 
5.9 
0.82 ± 
0.13 
0.99 ± 0.43 1193 ± 186 15.4 ± 
1.3 
1386 ± 
205 
3 15.7 ± 
0.7 
11.1 ± 0.5 265 ± 
20 
251 ± 
12 
CES (%)  10 10 20  – 10 10 – 10 10 10  – 10 10 10 – 10 – 10 – 10  10 10 10 10 
CED (mg/kg bw)  50.6 3.4 29.9  33.9 23.6 100.0 194.3 316.8  76.1 — 14.5 3.0 16.0 3.1  > 200 134.6 139.3 91.1 
BMDL (mg/kg 
bw) 
 29.9 1.6 22.9  18.9 7.4 70.8 142.7 197.5  55.5  4.1 1.6 4.8 1.6  129.8 86.7 69.9 49.3 
Ratio CED/BMDL  1.7 2.1 1.3  1.8 3.2 1.4 1.4 1.6  1.4  3.5 1.9 3.4 1.9  1.8 1.6 2.0 1.8 
Maximum 
response (% 
compared to 
control) 
 More 
than + 
41c 
+ 61 + 36  More 
than – 
45.3c 
+ 19.9 More 
than – 
17.1c 
+ 11.1 + 6.1  More 
than – 
23.5c 
 + 121 – 33.7 – 30.8 – 33.6  + 9 More than 
+ 15c 
More 
than + 
18c 
More 
than + 
31c 
BMDL (ID) (µg/g 
liver lipid, 
convertedd) 
 223 43 192  172 102 361 534 640  315  73 43 80 43  506 504 358 295 
BMDL (ID) (µg/g 
liver lipid, 
recalculatede) 
 — 39 112  — 121 253 209 267  209 — 64 — — —  149 148 141 130 
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Note. Figures are average ± SD of n replicates per dose group, CED values indicate critical effect dose at the given critical effect size (CES). ALP, alkaline 
phosphatase; CHOL, cholesterol; GLU, glucose; T4-UGT, T4-uridine diphosphate glucuronyl transferase; —, no significant dose-response or ratio 
CED/BMDL (ID) above 10.  
a
 Measured at femur and tibia metaphysis.  
b
 A similar dose-response is observed when activities are expressed per min per gram liver.  
c
 No plateau reached within the applied dose range.  
d
 For conversion external dose (ED)-internal dose (ID), the regression equation ID = 33377 x ED 0.5587 (with R2 = 0.79) was used.  
e
 For recalculations, which were applied for verification of the converted IDs, dose-responses were directly analyzed using ID as X-variable; differences 
between converted and recalculated BMDL (ID) values are probably mainly due to different size of the data sets; only three or even less animals per dose 
group were available for recalculation, with subsequent larger confidence interval variation (particularly with bone parameters). For this reason, the 
recalculated BMDL (ID) values are generally below the converted BMDL (ID) values, and the converted BMDL (ID) values should be considered more 
reliable.  
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TABLE 2 Significant HBCD-Induced Dose-Response Effects in Male Rats  
 Organ 
weights 
 
Spleen absolute cell numbers (x 107)) 
 
Plasma chemistry 
 
Liver 
 
HBCD dose n Thymus 
(g) 
n Total cells per 
spleen 
CD4 
(Th) 
CD161a 
(NK) 
n CHOL 
(mmol/l) 
GLU(mmol/l) Total protein 
(g/l) 
Albumin (g/l) n TT4 
(nmol/l) 
TT3 
(nmol/l) 
T4-UGT (pmol/min/mg 
protein)a 
 
0 5 0.47 ± 
0.08 
4 48.7 ± 10.5 14.0 ± 
4.7 
4.8 ± 1.2 5 2.08 ± 0.20 10.6 ± 1.1 56.4 ± 2.1 39.2 ± 1.0 5 40.2 ± 3.6 0.81 ± 
0.06 
0.36 ± 0.05 
0.3 5 0.45 ± 
0.08 
1 49.6 15.2 3.8 3 2.13 ± 0.31 10.4 ± 3.2 58.1 ± 2.9 39.1 ± 0.7 4–
5 
40.4 ± 5.0 0.84 ± 
0.14 
0.44 ± 0.15 
1 5 0.52 ± 
0.17 
2 47.1 ± 15.4 13.3 ± 
4.8 
3.6 ± 0.1 3 2.10 ± 0.23 10.3 ± 2.6 58.6 ± 2.2 39.7 ± 1.9 5 40.6 ± 5.3 0.85 ± 
0.16 
0.40 ± 0.14 
3 5 0.47 ± 
0.07 
1 44.4 11.4 4.6 3 1.74 ± 0.30 10.9 ± 1.8 58.1 ± 1.5 40.1 ± 0.3 5 49.4 ± 7.2 0.89 ± 
0.04 
0.69 ± 0.37 
10 4 0.50 ± 
0.09 
2 39.4 ± 3.8 10.5 ± 
0.9 
4.1 ± 1.2 3 2.01 ± 0.23 10.9 ± 2.5 57.6 ± 2.0 38.8 ± 1.2 5 43.3 ± 1.3 0.97 ± 
0.16 
0.60 ± 0.24 
30 5 0.37 ± 
0.06 
1 29.7 9 2.7 4 2.31 ± 0.41 10.5 ± 1.5 60.1 ± 1.2 39.2 ± 1.6 4–
5 
41.9 ± 4.6 0.90 ± 
0.13 
0.73 ± 0.26 
100 5 0.42 ± 
0.09 
1 37 11.2 2.9 4 1.99 ± 0.39 9.7 ± 2.6 61.4 ± 1.7 40.8 ± 1.8 4–
5 
35.4 ± 4.2 0.82 ± 
0.06 
0.99 ± 0.41 
200 5 0.38 ± 
0.13 
2 35.8 ± 1.1 10.0 ± 
2.0 
2.6 ± 0.1 3 1.63 ± 0.19 8.4 ± 1.2 59.6 ± 3.6 40.6 ± 1.8 5 41.4 ± 3.5 0.89 ± 
0.05 
0.88 ± 0.45 
CES (%)  20  20 20 20  10 10 10 10  10 10 10 
CED (mg/kg bw)  176.6  9.8 1.9 12.6  102.9 98.1 > 200 > 200  — — 1.1 
BMDL (mg/kg bw)  104.2  1.7 0.3 6.3  65.9 57 > 200 > 200    0.1 
Ratio CED/BMDL  1.7  5.8 6.3 3  1.6 1.7 1.7 1.8    11 
Maximum response (% 
compared to control) 
 – 20  – 28 – 33 – 41  Less than – 
21.2b 
Less than – 
19.7b 
5.2 More than + 
3.8b 
   106 
BMDL (ID) (µg/g liver lipid, 
convertedc) 
 113  8.5 2.9 19  85 77      — 
BMDL (ID) (µg/g liver lipid, 
recalculatedd) 
 52  — — —  — — 83 —  — — 21 
 
 
Note. Figures are average ± SD of n replicates per dose group. CHOL, cholesterol; GLU, glucose; T4-UGT, T4-uridine diphosphate glucuronyl transferase; —
, no significant dose-response or ratio CED/BMDL (ID) above 10.  
a
 A similar dose-response is observed when activities are expressed per min per gram liver.  
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BMDL values expressed as external doses were converted to internal doses (liver 
concentrations) using the regression equation between external and internal dose (Tables 1 
and 2). For verification, BMDLs were also recalculated based on internal doses, of which, 
however, maximal three data points per dose groups were available (Tables 1 and 2).  
The current experimental setup, with relatively few replicates per dose group, is not suitable 
for comparing individual dose groups due to limited statistical power. However, some 
parameters, which were targeted at discerning an overall difference rather than a dose-
response, were analyzed using conventional statistical tests. These included Fisher exact test 
(for distribution of histological scores of liver basophilia between controls and exposed 
specimen), two-way ANOVA (for variance of TSH immunostaining using dosing and gender 
as covariates), and a Student t-test (for comparing glucose concentrations between all males 
and all females).  
RESULTS 
  
In Life Observations 
Two male rats died from erroneous administration on exposure day 4. They were replaced 
since these animals were from a single dose group (3 mg/kg bw). Another rat (female, dose 
group 0.3 mg/kg bw) died from the same cause in the second week of exposure; this animal 
was not replaced. Two animals showed transient irritation of both eyes and three other 
animals had transient and limited skin irritations. These aberrations were not considered to be 
related to the exposure. There were no further clinical anomalies, dosing was well tolerated. 
All animals in all dose groups showed normal feed consumption. There were no effects on 
body growth during the exposure period (Supplementary Data Table 1).  
Internal HBCD Concentrations 
Analysis of HBCD-  and -  in the liver showed a dose-dependent increase with a plateau at 
the three highest doses (Fig. 1). Remarkably, the HBCD concentrations in the liver were 
higher in females than in males over the entire dose range (on average 5.2 times), and all 
females in the control group also had low levels of HBCD, whereas HBCD was below the limit 
of detection in control males. The average ratio / , which was approximately 8.1 in the 
administered technical mix, appeared to be 2.9 in females and 1.9 in males and decreased 
with dose in both sexes; at low doses, there was a higher contribution of the enantiomer, 
while at higher doses the ratio equalized or reversed. Similarly, the higher concentration of 
HBCD in female compared to male livers was mainly due to contributions of the enantiomer 
at low and the enantiomer at high doses. The lipid fraction in livers was not different between 
females and males, nor were there differences between dose groups. Analysis of fat samples 
of two animals of each sex in the 10 mg/kg bw dose groups revealed average HBCD values of 
379.5 and 84.9 mg/kg retroperitoneal fat tissue in females and males, respectively, that is, 2.4 
and 1.4 times higher than in liver lipid (not shown).  
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FIG. 1 Sum HBCD and in liver of female and male rats, after exposure to 0.3–200 mg/kg 
bw of technical mix for 28 days. Concentrations are expressed per gram of lipid on a 
logarithmic scale. There is a dose-dependent increase in both sexes up to a plateau in the 
three highest doses. Females tend to have higher concentrations than males. Averages are 
based on measurement of three animals per group; error bars indicate SD. For correlation 
equations, see Tables 1 and 2. 
Sperm Analysis 
Sperm collected from the epididymis during necropsy had similar characteristics in all dose 
groups (data available in Supplementary Data Table 2).  
Organ Weights 
There was a significant dose-dependent weight increase of the pituitary, the thyroid, and liver 
in females only. In males, there was only a decrease in thymus weight (Tables 1 and 2; 
Supplementary data Table 2). Dose-responses of spleen and kidney weights of female 
animals were too limited for calculation of BMDLs.  
The applied CES and corresponding BMDLs, both based on external doses and internal 
concentrations for these and other variables, are shown in Tables 1 and 2; details of weights 
of all organs are given in Supplementary Data Table 2. The deduction of a CED at a 
predefined CES is illustrated in Figure 2.  
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FIG. 2 Dose-response analysis illustrated with circulating TT4 in female rats. Method and 
parameters describing the curve were explained in Slob (2002). In this model, parameter a is 
the background level and b reflects the efficacy of exposure (slope). Log likelihood is used to 
assess to what extent the described curve deviates from no effect (y = a). CES, critical effect 
size, for TT4 set at 10% (horizontal dotted arrow); a corresponding critical effect dose (CED) 
is represented by the vertical dotted arrow. Exposure dose (x-axis) is on a logarithmic scale. 
Histopathology 
Histopathology of the thyroid showed that in HBCD-exposed females, thyroid follicles were 
smaller, depleted, and had activated, hypertrophied epithelium (Fig. 3A). Histopathological 
grading of the thyroid activation was based on assessment of follicle cell height, cellular 
vacuolization, and size of the nucleus, most of which showed a dose-related increase in both 
sexes, and scoring of follicle size, which showed a dose-related decrease in males (Table 3). 
Cell height and nuclear size were most sensitive, with initiation of the effect (a progression 
from slight to moderate activation, i.e., size) at intermediate doses, whereas effects in follicle 
size and cytoplasmic vacuolization only appeared at the high end of the dose range. In males, 
control thyroids were already moderately activated, and changes to advanced activation were 
therefore less obvious. There were no indications of hyperplasia.  
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FIG. 3 (A) Histology in the central thyroid of female rats, control (left panels) and after 28 days 
of exposure to 100 mg/kg bw HBCD (right panels) at low (top) and high (bottom) 
magnification. In the exposed sample, follicles are smaller or even depleted, the intrafollicular 
colloid (c) stains more faintly; cell height is increased (compare yellow arrows), nuclear size 
increased, and cells are more vacuolated (black arrow). All effects are illustrated at a 
moderate degree (see Table 3). (B) Morphometrical analysis of immunostained thyrotropic 
cells (top). The ratio between high and low saturation of TSH immunostaining was 
significantly increased in females exposed to the highest dose HBCD (p = 0.043, t-test). In the 
ANOVA, HBCD exposure accounted significantly for total variance (p = 0.038), while there 
was no significant effect of gender, nor is there interaction between variables. For both groups 
of female pituitaries n = 5 and n = 4 for both male groups. The microphotograph (bottom) is 
an image sample used for the morphometry with thin and thick arrows indicating low- and 
high-intensity staining cells. (C) Liver microphotographs of a control (left) and a HBCD (right)-
exposed female (100 mg/kg bw), illustrating increased basophilia in periportal zones after 
exposure (dark staining areas). A basophilic staining hepatocyte is indicated with an arrow, 
false color inserts show that there is more basophilia (black) in the HBCD-exposed liver. 
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TABLE 3 Doses of Progression for Histological Stages in the Thyroid  
 Females 
 
Males 
 
 Background 
stage 
CED for progression to next stage 
(mg/kg bw) 
Background 
stage 
CED for progression to next stage 
(mg/kg bw) 
 
Cell height 1 47 2 — 
Nuclear size 1 25 2 39 
Vacuolization 1 177 2 90 
Follicle size 1 — 1 199 
 
 
Note. Thyroids of all available animals (n = 38, females; n = 36 males) were evaluated for the 
histological parameters of the first column. Stages indicated size (cell, nucleus, and follicles), 
or degree of vacuolization (number and size of discernible vacuoles). CEDs are the critical 
effect doses in mg/kg body weight at which the average thyroid progresses to a further stage 
in a staging range 0–3, that is, reference, slight, moderate, and severe. Reference and 
moderate degree of effect in all four parameters is illustrated in Figure 3. For all four 
endpoints, there is a maximum progression of one stage. Male samples have higher 
background stages than female samples. Effects in cell height and nuclear size are initiated at 
intermediate doses (and reach a plateau at the end of the dose range). Effects in follicle size 
and cytoplasmic vacuolization are initiated at high doses.  
Immunohistochemical detection of TSH in the pituitary was done to elucidate whether 
activation of the thyroid epithelium was associated with increased expression of this 
stimulating hormone. Comparison of top dose animals with control animals showed a 
significantly increased ratio between high- and low-intensity immunostaining thyrotropic cells 
(Fig. 3B). When comparing dosed and control animals per gender, the effect was only 
significant in females, consistent with the increase of pituitary weight in females.  
In the liver, HBCD-exposed specimen of both sexes could be discerned on the basis of 
intense basophilia, specifically in periportal zones (Fig. 3C) to an accuracy of 60–80% by 
repeated blind scoring (not statistically significant, Fisher exact test). This visual effect is 
suggestive of endoplasmatic reticulum induction, compatible with increased synthetic activity, 
and is in line with the increased liver weights in females. There were no further apparent 
HBCD exposure associated changes in the liver, nor in the other organs assessed for 
histopathology, after analysis of the control and (sub-) top dose (n = 5 per sex per group; 
Supplementary Data Table 3). Inflammation in Langerhans islets was observed throughout all 
groups, independent of dosing. This insulitis was more severe in males than in females and 
associated with a gender difference regarding glucose concentrations (see below) but not 
related to exposure (not shown).  
Immunology/Hematology 
FACS analysis of immune cell populations in the spleen, which was only performed in male 
animals, revealed reduced total spleen cell count and counts of T-helper and NK cell 
subpopulations (Tables 1 and 2; Supplementary Data Table 4). Fractions of these cells did not 
change because counts of other subpopulations also declined, although not significantly. 
Cytotoxic activity of NK cells was also not affected. There were no effects on blood or bone 
marrow white blood cell populations (Supplementary Data Table 5). In hematological 
parameters, which were also only measured in males, there was a marginal decrease of the 
mean red blood cell volume, with a concomitant increase of mean erythrocyte hemoglobin 
concentration (Supplementary Data Table 6). Both changes were, however, below the CES.  
Clinical Chemistry 
Chemical analysis of plasma showed that female rats had decreased concentrations of 
alkaline phosphatase and glucose and increased cholesterol and total protein/albumin. Males 
had decreased cholesterol, increased total protein/albumin, and decreased glucose, all in a 
significant dose-dependent way (Tables 1 and 2; Supplementary Data Table 7). Plasma 
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glucose concentrations were higher in males compared to females (10.2 ± 2.1 in 40 males 
and 9.5 ± 1.2 mmol/l in 38 females), a nearly significant difference (p = 0.079).  
Thyroid Hormones and T4-UGT 
Measurement of thyroid hormones showed a dose-dependent decrease in total T4 (TT4) in 
females only (Tables 1 and 2; Supplementary Data Table 8); there were no effects on total T3 
(TT3) levels. In both male and female liver, a dose-dependent increase of T4-UGT activity was 
found (Tables 1 and 2; Supplementary Data Table 8). The BMDL was lower for male than for 
female rats (0.1 vs. 4.1), however, the high CED/BMDL ratio for T4-UGT in males implies high 
statistical uncertainty due to high variation of the data set, that is, general scatter (Tables 1 
and 2); therefore, the BMDL for this parameter is considered not valid.  
Liver Retinoids 
Marked dose-related decreases in apolar liver retinoid concentrations were observed in 
female rats (Tables 1 and 2; Supplementary Data Table 9). The decreases were parallel to 
the dose-related increase in liver weight (Tables 1 and 2; Supplementary Data Table 3). No 
effect on the apolar liver retinoid concentrations was seen in male rats (Table 9). The total 
contents of apolar retinoids in the liver were not affected by HBCD at any dose neither in 
female nor in male rats (Table 9).  
Bone Parameters 
In bone, the most consistent observation was an increase in mineral density of trabecular 
bone at femur and tibia metaphysis in female rats (Tables 1 and 2; Supplementary Data Table 
10). Further changes at the femur metaphysis of female rats were increased total bone area 
and increased total bone mineral contents. There were no changes in any of the bone 
parameters in male rats.  
DISCUSSION 
  
The BFR HBCD is a potentially persisting and bioaccumulating compound, of which low but 
significant exposure levels are found in humans (Fängström et al., 2006 ; Ryan et al., 2006). 
HBCD is suspected to interfere with the endocrine system (Legler and Brouwer, 2003). For 
these reasons, it was tested in a subacute toxicity study, enhanced for endocrine and immune 
endpoints.  
The daily gavage dosing resulted in dose-dependent liver concentrations of the compound, 
indicating bioavailability. The higher HBCD concentrations in females are consistent with 
results from a 90-day study in rats (Chengelis, 2001; cited in KEMI, 2003) and possibly due to 
a faster elimination in male compared to female rats (Yu and Atallah, 1980; cited in KEMI, 
2003). The excreted HBCD in that study, both in the feces and in the urine, was probably 
completely metabolized, indicating complete absorption of the orally dosed compound. Since 
activity of all assessed metabolizing enzymes, CYP1A1, CYP2B, CYP3A (Germer et al., 
2006), and T4-UGT (Tables 1 and 2) was lower or comparable in males compared to females 
(background and exposed), other mechanisms may play a role. The same mechanisms can 
also explain why HBCD was recovered from control female but not male animals, assuming 
that these control animals received traces of the compound, presumably, through the 
standard feed or from ambient contamination. In the 90-day study cited above, the HBCD 
concentrations in adipose tissue were 4–5 times higher than the concentrations in liver lipid in 
top dose animals in our study. Although comparison between these two studies is hampered 
by differences of preparations (acetone assisted solution in our study) and top doses (five 
times higher in the Chengelis study), a limited analysis in our study also showed higher 
concentrations in adipose tissue than in liver lipid.  
The /  HBCD isomer ratio in this study differed from the pattern in wildlife where HBCD 
dominates (Zegers et al., 2005). On the other hand, even the highest /  ratio in our rats was 
far lower than the /  ratio of the technical preparation used for exposure. This is in line with a 
higher susceptibility of the isomer to biodegradation compared to the isomer in CYP2B-
induced rat liver microsomes (Zegers et al., 2005). The decreasing /  ratio with increasing 
dose can then be understood as intensified biotransformation of the isomer with increasing 
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dose, whereas relatively more biotransformation-resistant isomer will accumulate. This effect 
may be enhanced by the induction of CYP2B (Germer et al., 2006). In this perspective, the 
different isomer ratios in our rats and in wildlife are most likely due to differences in exposure 
dose and duration.  
The most marked HBCD dose-related effects were on the TH axis, including decreased TT4, 
increased immunostaining for TSH in the pituitary, increased weight/activation of the pituitary 
and the thyroid glands, and induction of T4-UGT in the liver. All these effects were restricted 
to females, which is in line with the higher HBCD liver concentrations in females versus males, 
although contrasting with observations in a 90-day study by Chengelis (Chengelis, 2001; cited 
in KEMI, 2003), which showed decreased TT4, increased serum TSH, and thyroid gland 
activation in both sexes. Decreased TT4 can be considered as a relative insufficiency of the 
feedback (activation of pituitary/thyroid glands), that is, the imposed stress is beyond the 
exposure dose that can be adequately counterbalanced by an activated feedback system 
(McDermott and Ridgway, 2001). On the other hand, the feedback was sufficient to maintain 
physiological levels of the biological active TT3 in exposed animals, but even under these 
circumstances, decreased plasma TT4 levels can induce hypothyroidy-like effects, because 
plasma T4 is a source for intracellular T3 through deiodination (Escobar del Rey et al., 1989).  
The increased TSH immunostaining detected in the pituitary is likely an indicative of increased 
levels of circulating TSH in exposed animals, as measured in the 90-days study (Chengelis, 
2001; cited in KEMI, 2003). The increased weight of the pituitary must be due to indiscernible 
diffuse cellular hypertrophy and/or hyperplasia since no robust (clonal) changes were 
observed. Since, probably, only a limited number of the many cell populations of the pituitary 
are affected in a specific way, the detected slight weight increase of the pituitary may be 
symptomatic of a relatively strong effect in a single subpopulation, probably mainly the 
thyrotropic cells. The higher background activity observed in male thyroid histology, compared 
to control females, is in line with higher levels of circulating TSH in males than in females 
(Capen, 1997). The associated higher sensitivity for induction of proliferative lesions is not 
relevant here since these were not observed.  
One of several ways by which HBCD could induce hypothyroxinemia is through evoking a 
detoxification response in the liver, which concomitantly affects T4. Indeed, HBCD treatment 
led to induction of CYP2B and CYP3A (Germer et al., 2006). This is in line with the induction 
of UGT described here since there is coexpression of and functional cooperation between 
P450 and UGT enzymes (Ishii et al., 2005). The detoxification activity was stronger in female 
compared to male rats, consistent with the suggested histopathologic activation of the liver 
and increased liver weights in female rats, the latter also observed in a similar study 
(Chengelis, 1997; cited in KEMI, 2003). The higher sensitivity of females versus males for 
HBCD exposure could be enhanced by the lower binding capacity of TTR in female compared 
to male rats (Emerson et al., 1990). Since TTR is the major TH carrier protein in the adult rat 
(Schussler, 2000), T4 might thus be more available for metabolization in females compared to 
males.  
Other mechanisms which can induce hypothyroxinemia, such as direct interaction of HBCD 
with TH synthesis, or activation of other metabolizing enzymes (e.g., deiodinases, 
sulfotransferases) or cellular TH uptake were not explored in this study.  
Multiple mechanisms can be responsible for the observed effects on plasma parameters, 
including interaction of HBCD with many hormone receptors (Hamers et al., 2006). 
Furthermore, a physiologic relationship with the observed TH changes may possibly play a 
role, in view of the regulating potential of THs on metabolism. Specifically, associations 
between TH disruption and disregulation of metabolism of lipids/cholesterol (Fleischman and 
Shumaker, 1942), of serum proteins (Larsen and Davies, 2002), and of plasma glucose levels 
(Chidakel et al., 2005) are known. Some of these associations, partly also observed in a 
previous study (Chengelis, 2001; cited in KEMI, 2003), are gender specific. We cannot 
exclude that the effects on plasma glucose are biased by the insulitis which was present 
throughout the entire population of this experiment (and in other animals from the same 
source).  
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In general, decreased alkaline phosphatase in the plasma, as observed in the female rats, 
can be a marker of decreased activity of the liver or of osteoblasts. Both, however, appeared 
to be activated (increased liver weight, liver histopathology, and increased bone density). On 
the other hand, osteoblast alkaline phosphatase expression, which is TH dependent (Milne et 
al., 1998), could possibly be suppressed by HBCD through activation of TH-mediated effects 
(Hamers et al., 2006).  
The observed changes in the immune system (weight of spleen and thymus, spleen 
cellularity) are considered relevant because each imbalance in this system may reduce the 
homeostatic capacity of the individual. The effects on splenocyte counts should, however, be 
interpreted with caution due to small sample size and high CED/BMDL ratios, implicating 
statistical uncertainty. There is no unequivocal explanation for these effects, which may be 
related to a potential direct interaction of HBCD with steroid hormone or TH systems, the latter 
in view of the effects that TH can have on lymphocyte functions (Ong et al., 1986).  
The dose-dependent decrease of liver apolar retinoid concentrations in female rats probably 
reflects the dose-related increase in liver weight of these animals since there was no effect of 
HBCD on the total liver contents of apolar retinoids. Hepatic retinoid reduction has been 
proposed as an AhR-mediated response (Nilsson and Hakansson, 2002). Thus, the lack of 
retinoid effect, suggesting that HBCD does not activate the AhR, is consistent with the 
unaffected hepatic expression of CYP1A1/hepatic ethoxyresorufin-o-deethylase activity 
(Germer et al., 2006).  
Increased trabecular bone mineral density was observed at femur and tibia metaphysis in 
female rats, but there was no effect of HBCD on cortical bone at the diaphysis. This suggests 
that trabecular bone is more sensitive to the perturbations by HBCD compared to cortical 
bone, which may be related to the higher metabolic activity and turnover rate of trabecular 
compared to cortical bone (Ott, 2002). Since TH are involved in normal skeletal development, 
linear growth and the maintenance of adult bone mass (Bassett and Williams, 2003), the 
effect of HBCD in bone may be related with the observed hypothyroxinemia, supported by the 
occurrence of both effects in female rats only. Other mechanisms of action of HBCD can, 
however, not be excluded.  
Evaluation 
According to United States Environmental Protection Agency, adverse rodent noncancer 
thyroid effects due to chemically induced thyroid-pituitary disruption should be considered 
relevant to humans (Hill et al., 1998). In the current study, HBCD evoked a sequence of 
events in the TH system, specifically, in female rats. Apparently, these effects did not exceed 
the limits of homeostasis, in view of unaffected levels of circulating T3, but decreased plasma 
TT4 levels may well cause hypothyroidy-like effects. The initiating event is probably activation 
of liver enzymes (induction of T4-UGT at a BMDL of 4.1 mkd), resulting in increased liver 
weight at 22.9 mkd) with increased TH turnover (decreased TT4 at 55.5 mkd) and a feedback 
reaction in the pituitary (increased weight at 29 mkd, increased immunostaining intensity of 
TSH) and the thyroid gland (increased weight at 1.6 mkd, follicle cell activation at 25 mkd) as 
a consequence. Additional events, which may be secondary to changes in the TH system, 
include effects on plasma chemistry (notably, increased cholesterol at 7.4 mkd), bone 
parameters (49 mkd and higher), and spleen parameters (decreased splenocyte counts 0.3–
6.3 mkd, only assessed in males).  
Overall, female rats appear to be more sensitive to HBCD exposure than male rats, and a 
BMDL for adversity of HBCD, based on the most sensitive parameter, should be defined at 
1.6 mg/kg bw (equivalent to 43 µg HBCD/g liver) for the 10% increase of the thyroid weight. 
This is well below the previously proposed lowest observed adverse effect level (LOAEL) of 
100 mkd based on increased liver weight and disturbed TH system (Chengelis, 2001; cited in 
KEMI, 2003), and in the range of the LOAEL of 0.9 mkd based on behavioral effects in mice 
(Eriksson et al., 2006). Combined with recent exposure data in human breast milk, indicating 
HBCD levels which are at least four orders of magnitude below this BMDL (Fängström et al., 
2006; Ryan et al., 2006), this study does not support a major health risk of HBCD for humans.  
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SUPPLEMENTARY DATA 
  
Supplementary data are available online at http://toxsci.oxfordjournals.org/. Supplementary 
tables are provided to show average values with SD of body and organ weights and cauda 
epididymis sperm characteristics at necropsy, and a summary of histopathologic observations. 
For male rats only, average values with SD are provided of spleen subpopulations and NK 
activity, white cells in blood and bone marrow, and red blood cell parameters. Similar tables 
show average values with SD of clinical plasma chemistry, thyroid hormones and T4-UGT, 
retinoids in liver, and bone parameters of femur and tibia.  
NOTES 
  
This paper is dedicated to the memory of Prof Joseph G. Vos, inspiration of our endocrine 
disruption research, who died on May 15 2006.  
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